‘THIS IS WAR IN AMERICA’: CEO sounds the alarm on deadly drug crisis

Key Concepts

• Fentanyl Powder
• Fentanyl Vaccine (Immunotherapy)
• Armor Sciences (formerly the company with the vaccine)
• Overdose Prevention
• Clinical Trials
• Department of War Funding
• National Security Crisis
• Chemical Threat
• Mass Disruption
• War in America

Discovery of Fentanyl

The segment begins with an incident where authorities were alerted after a winning bidder for a storage unit discovered 12 kg of fentanyl powder. This discovery has prompted an investigation into the origin and intended recipients of the substance.

Fentanyl Vaccine Development and Progress

Colin Gage, CEO and co-founder of Armor Sciences (formerly the company developing the fentanyl vaccine), discusses the progress made over the past year.

• Company Rebranding: The company has been renamed Armor Sciences, with a mission to provide "armor" to citizens, starting with first responders.
• Vaccine Efficacy: The immunotherapy has demonstrated significant efficacy in blocking 98% of fentanyl and achieving a 100% elimination of behavioral effects in animal studies. This is crucial for preventing accidental overdoses, particularly among teenagers and college students who may unknowingly ingest fentanyl.
• Paradigm Shift: Gage emphasizes a proactive approach to preventing overdoses, contrasting it with the current reactive measures. He states, "WE NEED TO FLIP THAT PARADIGM AND BE PROACTIVE, PREVENT OVERDOSE, NOT REACT TO OVERDOSE."
• Clinical Trials: Clinical trials are planned to commence in January or February with healthy volunteers.
• Methodology for Trials: The trials will involve administering fentanyl to volunteers under the care of highly trained anesthesiologists in a medical setting. Treatments will be readily available in case of adverse events, though optimism regarding safety and efficacy is high.

Deployment Timeline and Regulatory Aspects

• Potential Deployment: Gage estimates that the vaccine could be on the market within 2 to 5 years, contingent on navigating various regulatory processes.
• Presidential Support: He notes that the current administration, particularly Donald Trump, is actively supporting efforts to combat the fentanyl crisis, indicating a strong political will to end it by any means necessary.

Funding and Perspective on the Fentanyl Crisis

• Funding Sources: Armor Sciences has been primarily funded by the Department of War, which views fentanyl as a chemical threat and a national security crisis.
• "Mass Disruption" and "War in America": One of the company's advisors, a former acting director of the DEA, describes the fentanyl crisis as a "mass disruption." Gage echoes this sentiment, stating, "NO SECRET THIS IS BEING DONE ON PURPOSE, WE ARE NOT LOSING HUNDREDS OF THOUSANDS OF INNOCENT LIVES BY ACCIDENT. THIS IS WAR IN AMERICA." This perspective frames the fentanyl crisis not as an accidental epidemic but as a deliberate act of aggression.

Conclusion

The discussion highlights a significant development in the fight against the fentanyl crisis with the progress of a novel immunotherapy vaccine by Armor Sciences. The vaccine aims to proactively prevent overdoses by blocking fentanyl's effects. While animal studies show robust efficacy, human clinical trials are slated to begin soon. The project is supported by government funding, reflecting the perception of fentanyl as a national security threat. The speakers express a strong conviction that the crisis is being orchestrated, leading to the characterization of the situation as "war in America."